- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 1.62 Å
- Oligo State
- homo-dimer
- Ligands
- 1 x NAG- NAG- MAN- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]alpha-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Non-covalent)
- 2 x N7F: 6-[(3S)-3-AMINOPIPERIDIN-1-YL]-5-BENZYL-4-OXO-3-(QUINOLIN-4-YLMETHYL)-4,5-DIHYDRO-3H-PYRROLO[3,2-D]PYRIMIDINE-7-CARBONITRILE(Non-covalent)
- 12 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.3: 3 residues within 4Å:- Chain A: R.109, I.110, N.112
5 PLIP interactions:5 interactions with chain A- Hydrophobic interactions: A:R.109
- Hydrogen bonds: A:R.109, A:R.109
- Water bridges: A:N.112, A:N.112
NAG.4: 4 residues within 4Å:- Chain A: N.181, T.183, Q.270, E.271
5 PLIP interactions:5 interactions with chain A- Hydrogen bonds: A:N.181, A:T.183, A:E.271, A:E.271
- Water bridges: A:T.183
NAG.5: 4 residues within 4Å:- Chain A: I.156, N.191, T.193, E.194
5 PLIP interactions:5 interactions with chain A- Hydrophobic interactions: A:I.156
- Hydrogen bonds: A:N.191, A:E.194, A:E.194
- Water bridges: A:T.227
NAG.6: 3 residues within 4Å:- Chain A: W.149, V.241, N.243
4 PLIP interactions:4 interactions with chain A- Water bridges: A:N.243, A:N.243, A:N.243, A:N.243
NAG.7: 6 residues within 4Å:- Chain A: I.281, N.283, M.310, S.311, T.312, R.558
4 PLIP interactions:4 interactions with chain A- Hydrogen bonds: A:R.558
- Water bridges: A:N.283, A:N.283, A:N.283
NAG.8: 4 residues within 4Å:- Chain A: L.481, N.482, R.543, D.567
2 PLIP interactions:2 interactions with chain A- Hydrogen bonds: A:R.543, A:R.543
NAG.16: 6 residues within 4Å:- Chain B: E.29, V.40, N.42, N.47, S.48, S.49
3 PLIP interactions:3 interactions with chain B- Hydrogen bonds: B:N.47
- Water bridges: B:E.29, B:N.42
NAG.17: 3 residues within 4Å:- Chain B: R.109, I.110, N.112
7 PLIP interactions:7 interactions with chain B- Hydrophobic interactions: B:R.109
- Hydrogen bonds: B:R.109, B:R.109
- Water bridges: B:Y.80, B:Y.80, B:N.112, B:N.112
NAG.18: 4 residues within 4Å:- Chain B: N.181, T.183, Q.270, E.271
4 PLIP interactions:4 interactions with chain B- Hydrogen bonds: B:N.181, B:E.271
- Water bridges: B:T.183, B:D.236
NAG.19: 4 residues within 4Å:- Chain B: I.156, N.191, T.193, E.194
5 PLIP interactions:5 interactions with chain B- Hydrophobic interactions: B:I.156
- Hydrogen bonds: B:N.191, B:E.194, B:E.194
- Water bridges: B:K.229
NAG.20: 3 residues within 4Å:- Chain B: W.149, V.241, N.243
4 PLIP interactions:4 interactions with chain B- Water bridges: B:N.243, B:N.243, B:N.243, B:N.243
NAG.21: 6 residues within 4Å:- Chain B: I.281, N.283, M.310, S.311, T.312, R.558
3 PLIP interactions:3 interactions with chain B- Hydrogen bonds: B:R.558, B:R.558
- Water bridges: B:N.283
- 6 x SO4: SULFATE ION(Non-functional Binders)
SO4.9: 4 residues within 4Å:- Chain A: R.558, R.559, D.640, N.641
2 PLIP interactions:2 interactions with chain A- Salt bridges: A:R.558, A:R.559
SO4.10: 4 residues within 4Å:- Chain A: T.106, E.107, E.108, R.109
3 PLIP interactions:3 interactions with chain A- Hydrogen bonds: A:E.108, A:R.109
- Salt bridges: A:R.109
SO4.11: 4 residues within 4Å:- Chain A: R.620, R.646
- Chain B: E.206, S.207
5 PLIP interactions:5 interactions with chain A- Water bridges: A:R.620, A:R.646, A:R.646
- Salt bridges: A:R.620, A:R.646
SO4.13: 4 residues within 4Å:- Chain B: T.106, E.107, E.108, R.109
4 PLIP interactions:4 interactions with chain B- Hydrogen bonds: B:T.106, B:E.108, B:R.109
- Salt bridges: B:R.109
SO4.14: 4 residues within 4Å:- Chain B: R.558, R.559, D.640, N.641
3 PLIP interactions:3 interactions with chain B- Hydrogen bonds: B:D.640
- Salt bridges: B:R.558, B:R.559
SO4.15: 4 residues within 4Å:- Chain A: E.206, S.207
- Chain B: R.620, R.646
2 PLIP interactions:2 interactions with chain B- Salt bridges: B:R.620, B:R.646
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Sutton, J.M. et al., Novel Heterocyclic Dpp-4 Inhibitors for the Treatment of Type 2 Diabetes. Bioorg.Med.Chem.Lett. (2012)
- Release Date
- 2012-02-08
- Peptides
- DIPEPTIDYL PEPTIDASE 4 SOLUBLE FORM: AB
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
B
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 1.62 Å
- Oligo State
- homo-dimer
- Ligands
- 1 x NAG- NAG- MAN- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]alpha-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Non-covalent)
- 2 x N7F: 6-[(3S)-3-AMINOPIPERIDIN-1-YL]-5-BENZYL-4-OXO-3-(QUINOLIN-4-YLMETHYL)-4,5-DIHYDRO-3H-PYRROLO[3,2-D]PYRIMIDINE-7-CARBONITRILE(Non-covalent)
- 12 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 6 x SO4: SULFATE ION(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Sutton, J.M. et al., Novel Heterocyclic Dpp-4 Inhibitors for the Treatment of Type 2 Diabetes. Bioorg.Med.Chem.Lett. (2012)
- Release Date
- 2012-02-08
- Peptides
- DIPEPTIDYL PEPTIDASE 4 SOLUBLE FORM: AB
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
B